CA2629364A1 - Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction - Google Patents

Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction Download PDF

Info

Publication number
CA2629364A1
CA2629364A1 CA002629364A CA2629364A CA2629364A1 CA 2629364 A1 CA2629364 A1 CA 2629364A1 CA 002629364 A CA002629364 A CA 002629364A CA 2629364 A CA2629364 A CA 2629364A CA 2629364 A1 CA2629364 A1 CA 2629364A1
Authority
CA
Canada
Prior art keywords
testosterone
analogue
tadalafil
compound capable
female sexual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002629364A
Other languages
French (fr)
Other versions
CA2629364C (en
Inventor
Jan Johan Adriaan Tuiten
Johannes Martinus Maria Bloemers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EB IP LYBRIDO BV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2629364A1 publication Critical patent/CA2629364A1/en
Application granted granted Critical
Publication of CA2629364C publication Critical patent/CA2629364C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

The invention relates to the field of female sexual dysfunction. It specifically relates to the influence of the combination of testosterone or an analogue thereof and tadalafil on sexual health in female subjects with Female Sexual Dysfunction (such as Female Sexual Arousal Disorder (FSAD) or Female Sexual Desire Disorder (FSDD)). It further relates to the influence of the combination of testosterone or an analogue thereof and a compound capable of at least in part inhibiting smooth muscle constriction, for example a compound capable of at least in part inhibiting the adrenergic tone. The invention further discloses other combinatorial therapies in the treatment of Female Sexual Dysfunction.

Claims (11)

1. Use of a combination of testosterone or an analogue thereof and tadalafil, in the preparation of a medicament for the treatment of female sexual dysfunction, wherein said testosterone or an analogue thereof and tadalafil are released at essentially the same time and wherein said testosterone or an analogue thereof is provided such that there is a peak of testosterone or an analogue thereof in the blood circulation of the subject to whom it is administered.
2. Use according to claim 1, wherein said testosterone or an analogue thereof and tadalafil are released within 30 minutes of each other.
3. A kit of parts comprising at least one pharmaceutical composition comprising testosterone or an analogue thereof and at least one pharmaceutical composition comprising tadalafil, wherein said kit further comprises instructions in respect to the administration of said compositions, preferably instructions to administrate said compositions at essentially the same time.
4. Use of a combination of testosterone or an analogue thereof and a compound capable of at least in part inhibiting the adrenergic tone in the preparation of a medicament for the treatment of FSD, wherein said testosterone or an analogue thereof is provided such that there is a peak of testosterone or an analogue thereof in the blood circulation of the subject to whom it is administered.
5. Use according to claim 4, wherein said compound capable of at least in part inhibiting the adrenergic tone is a postsynaptic adrenoceptor antagonist.
6. Use according to claim 4 or 5, wherein said compound capable of at least in part inhibiting the adrenergic tone is an alpha 1 adrenoreceptor antagonist, for example Prazosin, thymoxamine (moxisylyte), NMI-870, HMP12 or phentolamine.
7. Use according to claim 4, wherein said compound capable of at least in part inhibiting the adrenergic tone is an adrenergic autoreceptor agonist.
8. Use according to claim 4 or 7, wherein said compound capable of at least in part inhibiting the adrenergic tone is an alpha 2 adrenoreceptor agonist, for example clonidine or dexmedetomidine.
9. Use of a combination of testosterone or an analogue thereof and a compound capable of at least in part inhibiting the interaction between a GAF-A N-terminal domain and cGMP (for example a GAF-A blocker) in the preparation of a medicament for the treatment of female sexual dysfunction, wherein said testosterone or an analogue thereof is provided such that there is a peak of testosterone or an analogue thereof in the blood circulation of the subject to whom it is administered.
10. Use of testosterone or an analogue thereof and tadalafil, in the preparation of a medicament for the treatment of female sexual dysfunction, wherein said tadalafil is released prior to said testosterone or an analogue thereof and wherein said testosterone or an analogue thereof is provided such that there is a peak of testosterone or ann analogue thereof in the blood circulation of the subject to whom it is administered.
11. Use according to claim 10, wherein said tadalafil is released 2-14 hours prior to said testosterone or an analogue thereof.
CA2629364A 2005-11-11 2006-11-10 Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction Active CA2629364C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05077577A EP1790343A1 (en) 2005-11-11 2005-11-11 Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP05077577.4 2005-11-11
PCT/NL2006/000542 WO2007055563A2 (en) 2005-11-11 2006-11-10 Pharmaceutical combinations comprising testosterone in the treatment of female sexual dysfunction

Publications (2)

Publication Number Publication Date
CA2629364A1 true CA2629364A1 (en) 2007-05-18
CA2629364C CA2629364C (en) 2013-07-09

Family

ID=36118697

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2629364A Active CA2629364C (en) 2005-11-11 2006-11-10 Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction

Country Status (27)

Country Link
US (3) US9333203B2 (en)
EP (2) EP1790343A1 (en)
JP (2) JP2009515875A (en)
KR (5) KR20140070656A (en)
CN (2) CN101346143B (en)
AU (1) AU2006312373B2 (en)
BR (1) BRPI0618385A2 (en)
CA (1) CA2629364C (en)
CY (1) CY1122051T1 (en)
DK (1) DK1965802T3 (en)
EA (2) EA021540B1 (en)
ES (1) ES2744206T3 (en)
HK (1) HK1128226A1 (en)
HR (1) HRP20191544T1 (en)
HU (1) HUE045846T2 (en)
IL (1) IL191280A (en)
LT (1) LT1965802T (en)
ME (1) ME03499B (en)
NO (3) NO342986B1 (en)
NZ (1) NZ567963A (en)
PL (1) PL1965802T3 (en)
PT (1) PT1965802T (en)
RS (1) RS59268B1 (en)
SI (1) SI1965802T1 (en)
UA (2) UA97101C2 (en)
WO (1) WO2007055563A2 (en)
ZA (2) ZA200804443B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1750766E (en) 2004-05-11 2013-09-30 Emotional Brain Bv Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
JP6562630B2 (en) * 2011-05-13 2019-08-21 エーセラス ファーマシューティカルズ コーポレーション Low dosage concentration testosterone gel formulation for nasal administration and its use to treat aorgasmia or hyposexual desire disorder
CA2836405C (en) * 2011-05-15 2021-09-07 Trimel Biopharma Srl Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration
FR2999086B1 (en) * 2012-12-10 2015-04-10 Ethypharm Sa ORAL AND / OR ORAL COMPOSITION IN FINE FILM FORM OF A LOW SOLUBLE ACTIVE INGREDIENT, PROCESS FOR PREPARING THE SAME AND USE THEREOF
KR102476626B1 (en) 2014-11-14 2022-12-09 폴리 인터내셔널 System and method for preventing alopecia
ES2904543T3 (en) 2015-06-11 2022-04-05 ReJoy Treatment of sexual dysfunction
US11717495B2 (en) * 2020-03-16 2023-08-08 Vella Bioscience, Inc. Use of cannabinoids in treating anti-depressant-induced female sexual dysfunction

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3976776A (en) * 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
AU577802B2 (en) * 1983-10-17 1988-10-06 Duphar International Research B.V. Blood-pressure lowering piperazine derivatives
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4640921A (en) * 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
US5015646A (en) * 1987-08-28 1991-05-14 Bristol-Myers Squibb Co. Pharmaceutically useful polymorphic modification of buspirone
US4877774A (en) * 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
CA1335106C (en) * 1989-02-27 1995-04-04 John Mehnert Schaus Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes
US5447912A (en) 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
BR9408581A (en) 1994-06-02 1997-08-26 Dan Riga Anti-stress, anti-incapacitation and anti-aging medication and process for its production
RU2152787C2 (en) 1994-06-02 2000-07-20 Дан Рига Drug against stress, activity level decrease and ageing and method of its preparing
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5698560A (en) 1995-03-01 1997-12-16 Kyowa Hakko Kogyo Co., Ltd. Imidazoquinazoline derivatives
WO1996028142A1 (en) 1995-03-14 1996-09-19 Vivus, Incorporated Method and kit for preventing erectile dysfunction
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
CA2219082A1 (en) 1995-05-15 1996-11-21 Beth Israel Deaconess Medical Center, Inc. Use of dihydrotestosterone compounds for treating male sexual dysfunction
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US6251436B1 (en) * 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US5972614A (en) * 1995-12-06 1999-10-26 Genaissance Pharmaceuticals Genome anthologies for harvesting gene variants
US6287834B1 (en) * 1996-05-17 2001-09-11 Endorecherche, Inc. Characterization and use of an isolated uridine diphospho-glucuronosyltransferase
US6242198B1 (en) 1996-07-25 2001-06-05 Cambridge Neuroscience, Inc. Methods of treatment of eye trauma and disorders
DE69833254T2 (en) * 1997-06-23 2006-11-02 Cellegy Pharmaceuticals, Inc., Brisbane MICRODOSIS THERAPY OF VASCULAR EXPOSURE BY NO-DONORS
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
US20020013304A1 (en) 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
CA2306837C (en) * 1997-10-28 2007-05-08 Asivi, Llc. Treatment of female sexual dysfunction
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US6246436B1 (en) * 1997-11-03 2001-06-12 Agilent Technologies, Inc Adjustable gain active pixel sensor
TW542719B (en) * 1998-02-23 2003-07-21 Pfizer Res & Dev Method of treating impotence due to spinal cord injury
EP1084271A2 (en) * 1998-05-07 2001-03-21 Axys Pharmaceuticals, Inc. Genotyping the human udp-glucuronosyltransferase 1 (ugt1) gene
US6403605B1 (en) 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
US6448003B1 (en) * 1998-06-10 2002-09-10 Dna Sciences Laboratories, Inc. Genotyping the human phenol sulfotransferbase 2 gene STP2
US6407117B1 (en) * 1998-06-18 2002-06-18 The George Washington University Method of administering camptothecin compounds for the treatment of cancer with reduced side effects
US6319678B1 (en) * 1998-06-26 2001-11-20 Panvera Corporation Process for glucuronidation screening
US6586175B1 (en) * 1998-07-28 2003-07-01 Dna Sciences Laboratories, Inc. Genotyping the human UDP-glucuronosyltransferase 2B7 (UGT2B7) gene
UA67802C2 (en) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. CONTROLLED-RELEASE FORMULATIONS FOR ORAL ADMINISTRATION CONTAINING cGMP PDE-5 INHIBITOR (VARIANTS), METHOD FOR ITS PREPARATION AND METHOD FOR TREATING ERECTILE DYSFUNCTION
US6395481B1 (en) * 1999-02-16 2002-05-28 Arch Development Corp. Methods for detection of promoter polymorphism in a UGT gene promoter
US6613768B1 (en) 1999-04-30 2003-09-02 Lilly Icos Llc Treatment of female arousal disorder
US6428769B1 (en) * 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
US6632419B2 (en) * 1999-05-04 2003-10-14 Aradigm Corporation Increasing libido in humans via acute testosterone administration
US7258850B2 (en) 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
CA2377339A1 (en) 1999-06-17 2000-12-28 Armin Johannes Becker Administration of growth hormone (hgh) for the therapy of sexual functional disorders
RU2180591C2 (en) 1999-12-24 2002-03-20 Государственное научное предприятие Московский научно-исследовательский институт психиатрии МЗ РФ Agent for treatment of men with sexual disorders
DE10016548A1 (en) * 2000-04-03 2001-10-11 Bayer Ag Polyurethane dispersions
US6313172B1 (en) * 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6242436B1 (en) * 2000-06-15 2001-06-05 William Charles Llewellyn Use of 5alpha-androstanediol or 5alpha-androstanedione to increase dihydrotestosterone levels in humans
EP1325152A2 (en) * 2000-07-14 2003-07-09 F. Hoffmann-La Roche Ag Method for detecting pre-disposition to hepatotoxicity
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
ATE460939T1 (en) 2000-08-30 2010-04-15 Unimed Pharmaceuticals Llc METHOD FOR TREATING ERECTIVE DISORDER AND INCREASE LIBIDO IN MEN
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
SK287066B6 (en) 2000-09-29 2009-11-05 Solvay Pharmaceuticals B. V. Pharmaceutical formulation having a prolonged release and method of preparing this formulation
US20060287335A1 (en) * 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
ATE469966T1 (en) * 2000-12-12 2010-06-15 Inst Nagoya Ind Science Res METHOD FOR ESTIMATING THE RISK OF EXPRESSION OF AN ADVERSE DRUG EFFECT CAUSED BY THE ADMINISTRATION OF A COMPOUND EITHER PER SE METABOLIZED BY UGT1A1 OR WHICH INTERMEDIATE COMPOUND IS METABOLIZED BY THE ENZYME
US20020107230A1 (en) 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
DE10100238A1 (en) * 2001-01-05 2002-08-22 Hannover Med Hochschule Methods for predicting the potential risk for carcinoma and inflammatory bowel diseases and related tests
WO2002059375A2 (en) * 2001-01-26 2002-08-01 University Of Chicago Determination of ugt2b7 gene polymorphisms for predicting ugt2b7 substrate toxicity and for optimising drug dosage
WO2002069906A2 (en) 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
EA006154B1 (en) * 2001-03-28 2005-10-27 Пфайзер Инк. N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad
EP1260225A1 (en) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
US20030027804A1 (en) 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
US20030022875A1 (en) 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US20040203034A1 (en) * 2003-01-03 2004-10-14 The University Of Chicago Optimization of cancer treatment with irinotecan
US20040259852A1 (en) 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
EP1653966A1 (en) * 2003-07-16 2006-05-10 Pfizer Limited Treatment of sexual dysfunction
ATE319426T1 (en) * 2003-11-11 2006-03-15 Mattern Udo NASAL FORMULATION WITH CONTROLLED RELEASE OF SEXUAL HORMONES
WO2005094827A1 (en) 2004-03-30 2005-10-13 Kestrel Pharmaceuticals Inc. Methods for treating sexual dysfunction
KR20070014184A (en) 2004-04-22 2007-01-31 베링거 인겔하임 인터내셔날 게엠베하 New pharmaceutical compositions for the treatment of sexual disorders ii
PT1750766E (en) * 2004-05-11 2013-09-30 Emotional Brain Bv Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
KR20080016552A (en) * 2005-04-13 2008-02-21 유니메드 파마슈티칼스, 인크. Method of increasing testosterone and related steroid concentrations in women
WO2006127057A1 (en) 2005-05-24 2006-11-30 Lyle Corporate Drvelopment, Inc. Non-systematic vaginal administration of estrogen and an androgen for the treatment of sexual dysfunction
WO2006125642A1 (en) * 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
WO2007054791A2 (en) 2005-11-08 2007-05-18 L'oréal Androgen glucuronides as markers of androgenic activity
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) * 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
US8592477B2 (en) 2007-11-28 2013-11-26 Ucb Pharma Gmbh Polymorphic form of rotigotine and process for production

Also Published As

Publication number Publication date
WO2007055563A3 (en) 2007-09-07
US20170042911A1 (en) 2017-02-16
HUE045846T2 (en) 2020-01-28
JP2013241463A (en) 2013-12-05
EA034539B1 (en) 2020-02-18
PL1965802T3 (en) 2020-01-31
EA200801310A1 (en) 2009-04-28
ZA200903527B (en) 2010-04-28
KR20160128466A (en) 2016-11-07
CN103083325B (en) 2017-08-11
WO2007055563A2 (en) 2007-05-18
CA2629364C (en) 2013-07-09
CN103083325A (en) 2013-05-08
NO342986B1 (en) 2018-09-17
UA97101C2 (en) 2012-01-10
LT1965802T (en) 2019-09-10
ZA200804443B (en) 2009-10-28
EP1790343A1 (en) 2007-05-30
KR20150110829A (en) 2015-10-02
NO20082703L (en) 2008-07-31
NO20170800A1 (en) 2008-07-31
US9333203B2 (en) 2016-05-10
ES2744206T3 (en) 2020-02-24
AU2006312373A1 (en) 2007-05-18
KR20170029011A (en) 2017-03-14
NZ567963A (en) 2012-04-27
DK1965802T3 (en) 2019-09-16
US9737548B2 (en) 2017-08-22
UA112406C2 (en) 2016-09-12
CY1122051T1 (en) 2020-10-14
BRPI0618385A2 (en) 2011-08-30
IL191280A0 (en) 2009-08-03
RS59268B1 (en) 2019-10-31
KR20140070656A (en) 2014-06-10
EP1965802A2 (en) 2008-09-10
KR20080084943A (en) 2008-09-22
HRP20191544T1 (en) 2019-11-29
US20160213683A1 (en) 2016-07-28
ME03499B (en) 2020-04-20
PT1965802T (en) 2019-09-19
EA201400423A1 (en) 2015-01-30
NO20170799A1 (en) 2008-07-31
CN101346143B (en) 2013-01-30
NO343941B1 (en) 2019-07-22
JP2009515875A (en) 2009-04-16
EP1965802B1 (en) 2019-06-05
AU2006312373B2 (en) 2013-01-10
SI1965802T1 (en) 2019-10-30
US20090306026A1 (en) 2009-12-10
HK1128226A1 (en) 2009-10-23
EA021540B1 (en) 2015-07-30
JP5959483B2 (en) 2016-08-02
IL191280A (en) 2016-02-29
CN101346143A (en) 2009-01-14

Similar Documents

Publication Publication Date Title
CA2629364A1 (en) Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
BRPI0611705A2 (en) compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, and use of compound
AR044007A1 (en) METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE
EP4272818A3 (en) Thrombolytic agent for the treatment of thromboembolism
MX2010002392A (en) Improved brimonidine compositions for treating erythema.
CY1126152T1 (en) RIP1 INHIBITOR COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF
AR068185A1 (en) COMPOSITIONS OF LAMOTRIGIN ORAL DISINTEGRATION TABLETS
RU2009120992A (en) 3-ANDROSTANEDIOL USE, OPTIONAL IN COMBINATION WITH A 5-HT1A AGONIST FOR TREATMENT OF SEXUAL DYSFUNCTION
MX2010004281A (en) Compositions and methods for treatment of diabetic retinopathy.
MY143795A (en) Tetrahydropyridoindole derivatives
UA88463C2 (en) Pharmaceutical composition comprising compound i and method of treating hiv infection
MX2009003122A (en) Inhibitors of bruton's tyrosine kinase.
WO2007120528A3 (en) Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases
AR115585A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF FAT INFILTRATION IN MUSCLE
CO2020009670A2 (en) Compositions comprising the co-selected microbiota and methods for their use
EA200971107A1 (en) CATECHOLAMINE DERIVATIVES, USEFUL FOR THE TREATMENT OF PARKINSON'S Disease
EA202191079A1 (en) METHODS FOR TREATMENT OF RETTA SYNDROME WITH FENFLURAMINE
MA32967B1 (en) SGC stimuli for SGC stimulants in combination with PDE5 inhibitors in the treatment of erectile dysfunction
EA200800397A1 (en) TIZANIDINE COMPOSITIONS AND TREATMENT METHODS USING COMPOSITIONS
BRPI0514250A (en) use of a compound, pharmaceutical composition comprising the same, compounds and method of treatment
AU2006342119A8 (en) Soluble human M-CSF receptor and uses thereof
WO2007014943A3 (en) Therapy for neurological diseases
MXPA05013016A (en) Aboxadol for treating depression and other affective disorders.
RU2012114189A (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FUNGAL INFECTIONS
MX2020004397A (en) Use of amino acid supplementation for improved muscle protein synthesis.

Legal Events

Date Code Title Description
EEER Examination request